Canada OKs dose of Bristol-Myers' HIV drug

Published: May 17, 2007 at 10:17 AM

MONTREAL, May 17 (UPI) -- Bristol-Myers Squibb said Thursday Health Canada approved a once-daily, 300 mg pill of Reyataz for treating HIV infection.

The new dose of the protease inhibitor can be taken once daily as part of combination therapy, replacing two Reyataz 150 mg capsules.

"Bristol-Myers Squibb is committed to helping lead the development and production of innovative once-daily HIV medicines," said Wayne Quigley, president and general manager of Bristol-Myers Squibb Canada. "With the Reyataz 300 mg single-capsule formulation approval, Bristol-Myers Squibb now has one pill, once-daily HIV medicine option available in three drug classes, as part of combination therapy."

The company said it will continue to produce both the 150 mg and 200 mg formulations of Reyataz.

© 2007 United Press International, Inc. All Rights Reserved.
Order reprints



Additional News Stories
Jockstrip: The world as we know it. (14 min)
Your Daily Horoscope
The almanac
NBA: LA Clippers 97, Washington 95
Teachers influence if kids play sports
Report: Series hero Matsui joins Angels
Workers paid hourly may be happier
fark
Swedish troops in Afghanistan in trouble for not paying local women for "massages". Tune in next...
Just in time for Christmas, veterinarian becomes the first in the world to perform a laproscopic...
"He smelled like alcohol. So I knew it wasn't the real Santa because Santa doesn't drink alcohol"...
Need a last minute gift idea? How about sending a loved one to a re-creation of a German POW Camp...
Photoshop these standing stones
Remember the Brit who was arrested after beating an attacker who took his family hostage? The Nanny...